#MPNSM Vikas Gupta - Ruxolitinib followed by reduced intensity transplant for MF - Graft failure still a significant problem - bbmt.org/article/S1083-…

Health care is a tangle of conflicting expectations of patients, clinicians, policy makers ja.ma/1JTYXpZ

Version 2.0 of Canadian MPN group website is launched today!! We look forward to feedback 4 continuous improvement mpncanada.com

#MPNSM-EZH2/JAK2 interaction in mouse model of MPN: Loss of Ezh2 cooperates with Jak2 in the development of MF - ncbi.nlm.nih.gov/pubmed/2708109…

#MPNSM - Sexual function and MPN - Role of sexuality symptoms in MPN symptom burden and Quality of life... - - NCBI ncbi.nlm.nih.gov/pubmed/2707013…

#MPNSM - Splenomegaly and age as risk factors for poor graft function after HCT for myelofibrosis. - PubMed - NCBI ncbi.nlm.nih.gov/pubmed/2708837…

#MPNSM- 80 week FU of RESPONSE trial (Ruxolitinib vs. BAT) for Polycythemia Vera - PubMed - NCBI ncbi.nlm.nih.gov/pubmed/2710249…

#MPNSM Vikas Gupta - The problem of recurrent venous thromboembolism in patients with MPN. - PubMed - NCBI ncbi.nlm.nih.gov/pubmed/2711381…

#mpnsm: A large cohort experience with ruxolitinib in a phase 3b expanded-access study in pts with myelofibrosis haematologica.org/content/early/…

The first newsletter for the Candaian MPN Group #mpnsm mpncanada.com/site/wp-conten…

#mpnsm @ Vikas_Gupta_1 MPN Canada - Laboratory Investigation of Myeloproliferative Neoplasms (MPNs) ajcp.oxfordjournals.org/content/146/4/…

#mpnsm - Fall newsletter of the canadian MPN group - mpncanada.com/site/wp-conten…

#mpnsm -Targeted sequencing in myelofibrosis-ASXL1,SRSF2,CBL,KIT, RUNX1, SH2B3, CEBPA associated with poor prognosis bloodadvances.org/content/1/2/105

Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms bloodadvances.org/content/1/15/1…

Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy bloodadvances.org/content/1/20/1…

#MPNSM - SIMPLIFY-1: Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Myelofibrosis: JCO 2017: ascopubs.org/doi/full/10.12…

#mpnsm - quarterly newsletter of the Canadian MPN group mpncanada.com/site/wp-conten…

#MPNSM - Clinical rationale for targeted therapy for Rux+IDH2 inhibitors - JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition jci.org/articles/view/…

#mpnsm-use of NGS in routine clinical work flow - data from princess Margaret. x.com/eha_hematology…

#mpnsm - 73% of respondents do not use interferon for MF; some use in routine care and some as part of clinical trial, results suggestive of uncertainty of current literature and need for well designed trials to understand the role of interferon in MF x.com/vikas_gupta_1/…